Borg S - Search Results

1

Costs of COPD in Sweden according to disease severity.

Jansson SA, Andersson F, Borg S, Ericsson A, Jönsson E, Lundbäck B. Jansson SA, et al. Among authors: borg s. Chest. 2002 Dec;122(6):1994-2002. doi: 10.1378/chest.122.6.1994. Chest. 2002. PMID: 12475838

2

Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.

Hofmarcher T, Borg S. Hofmarcher T, et al. Among authors: borg s. J Med Econ. 2015;18(7):492-501. doi: 10.3111/13696998.2015.1029491. Epub 2015 Mar 31. J Med Econ. 2015. PMID: 25766863 Clinical Trial.

3

Cost differences for COPD with and without physician-diagnosis.

Jansson SA, Lindberg A, Ericsson A, Borg S, Rönmark E, Andersson F, Lundbäck B. Jansson SA, et al. Among authors: borg s. COPD. 2005 Dec;2(4):427-34. doi: 10.1080/15412550500346501. COPD. 2005. PMID: 17147008

4

The Swedish cost burden of overweight and obesity--evaluated with the PAR approach and a statistical modelling approach.

Odegaard K, Borg S, Persson U, Svensson M. Odegaard K, et al. Among authors: borg s. Int J Pediatr Obes. 2008;3 Suppl 1:51-7. doi: 10.1080/17477160801897067. Int J Pediatr Obes. 2008. PMID: 18278633

5

Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.

Persson U, Borg S, Jansson S, Ekman T, Franksson L, Friesland S, Larsson AM. Persson U, et al. Among authors: borg s. Adv Ther. 2005 May-Jun;22(3):208-24. doi: 10.1007/BF02849930. Adv Ther. 2005. PMID: 16236682

6

Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden.

Tunsäter A, Moutakis M, Borg S, Persson U, Strömberg L, Nielsen AL. Tunsäter A, et al. Among authors: borg s. Health Policy. 2007 May;81(2-3):309-19. doi: 10.1016/j.healthpol.2006.05.013. Epub 2006 Aug 14. Health Policy. 2007. PMID: 16904788

7

Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.

Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, Risebrough NA, Slejko JF, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: borg s. Int J Chron Obstruct Pulmon Dis. 2017 Nov 1;12:3183-3194. doi: 10.2147/COPD.S142378. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29138546 Free PMC article.

8

Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.

Hoogendoorn M, Feenstra TL, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs AH, Lloyd A, Sullivan SD, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: borg s. Value Health. 2014 Jul;17(5):525-36. doi: 10.1016/j.jval.2014.03.1721. Epub 2014 May 14. Value Health. 2014. PMID: 25128045

9

Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort.

Gerdtham UG, Andersson LF, Ericsson A, Borg S, Jansson SA, Rönmark E, Lundbäck B. Gerdtham UG, et al. Among authors: borg s. Eur J Health Econ. 2009 May;10(2):217-26. doi: 10.1007/s10198-008-0121-6. Epub 2008 Oct 14. Eur J Health Econ. 2009. PMID: 18853206

10

Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.

Borg S, Persson U, Allikmets K, Ericsson K. Borg S, et al. Clin Ther. 2006 Nov;28(11):1947-59. doi: 10.1016/j.clinthera.2006.11.013. Clin Ther. 2006. PMID: 17213015

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results